SYMPLIFY, a prospective observational study, is the first large-scale evaluation of a multi-cancer early detection (MCED) test in individuals who presented with symptoms to primar ...

The fact that fake scientists with a publication history were invited to review papers more often than were those without ...

How much alcohol is “too much,” in terms of cancer risk? Identifying causes helps us make decisions — both as individuals and ...

Dow Jones futures advance 0.37% to rise near 46,550 during European hours, ahead of the opening of the United States (US) ...

Uncertainty is ubiquitous in the practice of medicine. This review characterizes clinical uncertainty and shows how teachers ...

Data at ESMO 2025 bolstered the case that blood tests could help doctors sort which patients need additional therapy, and who ...

Summer McKesson’s quest for answers to her medical condition would unearth a family secret – and a doctor’s decades-old deception that has ensnared multiple families across the country.

The FDA has cleared Elecsys pTau181, the first blood test for use in primary care to help rule out Alzheimer’s disease in ...

National AI usage among businesses is 9.2%, with a projected increase to 11.6% in six months. Utah leads state AI business adoption at 15.7%%; Delaware's projected rate is highest at 19.1%.

The Magnificent Seven represent 36.6% of the S&P 500 as of October 2025, up from 12.3% in 2015. From 2015 to 2024, these seven companies achieved a 697.6% return, outperforming the S&P 500. The S&P ...